Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006007 · ClinicalTrials.gov registry record · Phase 2

LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
59
Enrollment target
20
Study locations

NCT00006007 is a Phase 2 study of Breast Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 59 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006007, a Phase 2 study of Breast Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
59 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining LY231514 plus gemcitabine in treating women who have metastatic breast cancer.

Conditions Studied

Breast Cancer

Interventions

  • DRUG gemcitabine hydrochloride
  • DRUG pemetrexed disodium

Study Locations (20)

Minnesota

  • CCOP - Duluth - Duluth
  • Mayo Clinic Cancer Center - Rochester
  • CentraCare Health Plaza - Saint Cloud
  • CCOP - Metro-Minnesota - Saint Louis Park

Illinois

  • CCOP - Illinois Oncology Research Association - Peoria
  • Illinois Oncology Research Association - Peoria
  • CCOP - Carle Cancer Center - Urbana

Iowa

  • CCOP - Cedar Rapids Oncology Project - Cedar Rapids
  • CCOP - Iowa Oncology Research Association - Des Moines
  • Siouxland Hematology-Oncology - Sioux City

North Dakota

  • Medcenter One Health System - Bismarck
  • CCOP - Merit Care Hospital - Fargo
  • Altru Health Systems - Grand Forks

Arizona

  • CCOP - Scottsdale Oncology Program - Scottsdale

Florida

  • Mayo Clinic - Jacksonville

Kansas

  • CCOP - Wichita - Wichita

Louisiana

  • CCOP - Ochsner - New Orleans

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2000-12
Est. Completion 2008-05
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00006007

The ClinicalTrials.gov registry entry for NCT00006007 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.

NCT00006007 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Minnesota, Illinois, Iowa.

Frequently Asked Questions

What is clinical trial NCT00006007 about?

NCT00006007 is a clinical study titled "LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining LY231514 plus gemcitabine in treating women who have metast...

What is the current status of trial NCT00006007?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2000-12. Estimated completion is 2008-05.

What conditions does trial NCT00006007 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00006007?

The interventions under investigation include: gemcitabine hydrochloride (DRUG), pemetrexed disodium (DRUG).

Who is sponsoring clinical trial NCT00006007?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006007 being conducted?

This trial has 20 study locations across Arizona, Florida, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.